Senolytic Interventions for Type 2 Diabetes : Current Evidence and Future Directions
Sodini, Selene LU
and Suarez-Ortegón, Milton Fabián
(2025)
In Diabetology
6(6).
- Abstract
Cellular senescence, a phenomenon characterized by the accumulation of dysfunctional, metabolically active cells, is increasingly recognized to be a key player in aging-related metabolic disorders. It is accelerated by hyperglycemia through various molecular pathways, positioning it as a critical mechanism in the pathophysiology of type 2 diabetes mellitus (T2D) and a potential therapeutic target. Emerging evidence from animal and clinical studies suggests that the usage of senolytic drugs, which selectively deplete senescent cells, can improve blood glucose regulation and mitigate diabetic complications. However, despite the conceptual feasibility of this approach, several challenges remain in their translation to the clinic: the... (More)
Cellular senescence, a phenomenon characterized by the accumulation of dysfunctional, metabolically active cells, is increasingly recognized to be a key player in aging-related metabolic disorders. It is accelerated by hyperglycemia through various molecular pathways, positioning it as a critical mechanism in the pathophysiology of type 2 diabetes mellitus (T2D) and a potential therapeutic target. Emerging evidence from animal and clinical studies suggests that the usage of senolytic drugs, which selectively deplete senescent cells, can improve blood glucose regulation and mitigate diabetic complications. However, despite the conceptual feasibility of this approach, several challenges remain in their translation to the clinic: the molecular mechanisms underlying the pathogenicity of cellular senescence in vivo remain incompletely understood, and organ-specific effects of senolytic administration are yet to be fully elucidated to ensure their safety and efficacy in clinical applications. This review explores the characteristics of cellular senescence and the senescence-associated secretory phenotype (SASP) in key tissues involved in glucose homeostasis, including the pancreas, liver, adipose tissue, and skeletal muscle and the potential applications of targeting cellular senescence as a therapeutic strategy for T2D management.
(Less)
- author
- Sodini, Selene
LU
and Suarez-Ortegón, Milton Fabián
- organization
- publishing date
- 2025-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- aging, cellular senescence, diabetes mellitus type 2, insulin-secreting cells, senolytics, senomorphics
- in
- Diabetology
- volume
- 6
- issue
- 6
- article number
- 48
- publisher
- MDPI AG
- external identifiers
-
- scopus:105009312136
- ISSN
- 2673-4540
- DOI
- 10.3390/diabetology6060048
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2025 by the authors.
- id
- 1d61c67d-5586-4d0b-ab75-a493c3600e06
- date added to LUP
- 2025-12-16 10:15:24
- date last changed
- 2025-12-16 10:16:16
@article{1d61c67d-5586-4d0b-ab75-a493c3600e06,
abstract = {{<p>Cellular senescence, a phenomenon characterized by the accumulation of dysfunctional, metabolically active cells, is increasingly recognized to be a key player in aging-related metabolic disorders. It is accelerated by hyperglycemia through various molecular pathways, positioning it as a critical mechanism in the pathophysiology of type 2 diabetes mellitus (T2D) and a potential therapeutic target. Emerging evidence from animal and clinical studies suggests that the usage of senolytic drugs, which selectively deplete senescent cells, can improve blood glucose regulation and mitigate diabetic complications. However, despite the conceptual feasibility of this approach, several challenges remain in their translation to the clinic: the molecular mechanisms underlying the pathogenicity of cellular senescence in vivo remain incompletely understood, and organ-specific effects of senolytic administration are yet to be fully elucidated to ensure their safety and efficacy in clinical applications. This review explores the characteristics of cellular senescence and the senescence-associated secretory phenotype (SASP) in key tissues involved in glucose homeostasis, including the pancreas, liver, adipose tissue, and skeletal muscle and the potential applications of targeting cellular senescence as a therapeutic strategy for T2D management.</p>}},
author = {{Sodini, Selene and Suarez-Ortegón, Milton Fabián}},
issn = {{2673-4540}},
keywords = {{aging; cellular senescence; diabetes mellitus type 2; insulin-secreting cells; senolytics; senomorphics}},
language = {{eng}},
number = {{6}},
publisher = {{MDPI AG}},
series = {{Diabetology}},
title = {{Senolytic Interventions for Type 2 Diabetes : Current Evidence and Future Directions}},
url = {{http://dx.doi.org/10.3390/diabetology6060048}},
doi = {{10.3390/diabetology6060048}},
volume = {{6}},
year = {{2025}},
}